Heart Failure Duration Combined with Left Atrial Dimension Predicts Super-Response and Long-Term Prognosis in Patients with Cardiac Resynchronization Therapy Implantation
Table 1
Baseline characteristics of patients between super-responders and non-super-responders.
characteristics
Total population
super-responders
non-super-responders
P Value
(n=73)
(n=17)
(n=56)
Age (years)
60.32 ± 9.78
60.00 ± 9.87
61.35 ± 9.72
0.621
Gender (female)
21 (28.8%)
7 (41.2%)
14 (25.0%)
0.197
NYHA class
3 (3-3)
3 (2-3)
3 (3-3)
0.285
HF duration (months)
48 (18-78)
12 (6-60)
60 (27-96)
< 0.001
Hypertension, n (%)
16 (21.9%)
5 (29.4%)
11 (19.6%)
0.394
Diabetes, n (%)
8 (11.0%)
3 (17.6%)
5 (8.9%)
0.378
Atrial fibrillation, n (%)
9 (12.3%)
1 (5.9%)
8 (14.3%)
0.675
Ischemic etiology, n (%)
12 (16.4%)
4 (23.5%)
8 (14.3%)
0.456
LVEF (%)
32 (27-34)
32.6 (28-35)
31 (25-33.75)
0.140
LAD (mm)
45 (39.75-47)
40 (38-42)
46 (41.23-48)
0.001
LVEDD (mm)
70.22 ± 7.98
68.25 ± 8.37
70.82 ± 7.84
0.247
MR (cm2)
7.0 (4.5-9.98)
5.99 (4.30-7.55)
7.32 (4.5-10.41)
0.079
QRS duration (ms)
164.0 ± 20.99
171.2 ± 16.54
161.9 ± 21.83
0.109
LBBB, n (%)
46 (63.0%)
15 (88.2%)
31 (55.4%)
0.020
ACE-I/ARB, n (%)
67 (91.8%)
16 (94.1%)
51 (91.1%)
1.000
Beta-blockers, n (%)
66 (90.4%)
16 (94.1%)
50 (89.3%)
1.000
Spironolactone, n (%)
61 (83.6%)
15 (88.2%)
46 (82.1%)
0.720
Values are mean ± SD, median (range), or n (%). NYHA: New York Heart Association; HF: Heart Failure; LVEF: left ventricular ejection fraction; LAD: left atrial dimension; LVEDD: left ventricular end-diastolic dimension; MR: mitral regurgitation; LBBB: left bundle branch block; ACEI: angiotensin-converting-enzyme inhibitor; ARB: angiotensin receptor blocker.
